Home » Newsletters » BioWorld Science

BioWorld Science

May 7, 2007

View Archived Issues

Trials assessing the efficacy of drugs for restless legs syndrome

Preclinical activity of the novel Aurora kinase inhibitor AZD-1152 profiled at the AACR meeting

Novel antiinflammatory agents disclosed in recent patents

Effects of NGX-4010 assessed in HIV-associated distal sensory polyneuropathy

New preclinical data on GSK-923295 reported by GSK and Cytokinetics

Recent patent from Astellas describes novel xanthine oxidase inhibitors

Recent patents disclose new therapeutic agents for anxiety and depression

Preclinical findings on the anti-DR5 agonist antibody LBY-135 reported by Novartis

Potent antitumor and antiangiogenic activity of LP-261 alone or in combination with bevacizumab

Platencin shows antibiotic activity in vivo via inhibition of fatty acid biosynthesis

Purdue Research Foundation licenses flu vaccine candidate to PaxVax

CyDex licenses Captisol enabling technology to Proteolix

Second phase III study begins for OPT-80 in CDAD

Sapacitabine studied in new phase II trial for advanced CTCL

Iplex demonstrates efficacy in HARS

NGD-4715 for obesity completes first-in-man study

Study establishes proof of concept for PRO-140 as antiretroviral agent

Oral cethromycin 100% protective against lethal dose of inhaled anthrax

A novel SIRT1 activator from Sirtris shows neuroprotective effects in optic neuritis in vivo

In vivo antiangiogenic activity of Immusol's new compound, IMS-2186

6R-BH4 enters phase IIa study for sickle cell disease

Treatment complete in phase III study of TH-9507 in HIV-associated lipodystrophy

Expression Genetics receives grant for development of EGEN-001 in ovarian cancer

PrimoVax study of GV-1001 cleared to open in U.S.

Quest advances SL-052 for prostate cancer in preclinical testing

Pivotal trials begin for EOquin in noninvasive bladder cancer

Lux receives Canadian clearance for phase II/III trials of LX-211 in uveitis

IND clearance for study of allogeneic adult stem cells in heart attack patients

Vyvanse receives DEA schedule classification

Ista receives non approvable letter for T-Pred

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...